Event Overview

VLS-101 is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) in Richter’s Syndrome (RS)


Tiziana Vaisitti, PhD, Katti Jessen, PhD, Thanh-Trang Vo, PhD, Mira Ko, Francesca Arruga, PhD, Nicoletta Vitale, PhD, Esteban Braggio, PhD, Arianna Di Napoli, Amy Chadburn, MD, John N. Allan, MD, Richard R. Furman, MD, Langdon L. Miller, Brian J. Lanutti, PhD, Silvia Deaglio, MD PhD

Supporting Materials


Now Leaving The VelosBio Site.

VelosBio Inc. is now a wholly-owned subsidiary of Merck & Co., Inc. (Kenilworth, New Jersey USA)

CLICK TO VISIT www.merck.com